Free Trial
→ Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000” (From Colonial Metals) (Ad)

Glaukos Q2 2024 Earnings Report

Glaukos logo
$126.03 -31.33 (-19.91%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Glaukos EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.52
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.55

Glaukos Revenue Results

Actual Revenue
$95.70 million
Expected Revenue
$88.86 million
Beat/Miss
Beat by +$6.84 million
YoY Revenue Growth
+19.00%

Glaukos Announcement Details

Quarter
Q2 2024
Date
7/31/2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Powered by Quartr

Glaukos Earnings Headlines

Glaukos price target raised to $176 from $149 at Needham
February 22 at 7:35 AM | markets.businessinsider.com
Glaukos price target raised to $160 from $153 at Wells Fargo
February 22 at 2:34 AM | markets.businessinsider.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Glaukos (NYSE:GKOS) Shares Gap Down on Disappointing Earnings
February 22 at 1:53 AM | americanbankingnews.com
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
February 21 at 5:03 AM | seekingalpha.com
Glaukos down 14% at $135 after Q4 results and guidance
February 21 at 1:37 AM | markets.businessinsider.com
See More Glaukos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Glaukos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Glaukos and other key companies, straight to your email.

About Glaukos

Glaukos (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

View Glaukos Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles